CA3201273A1 - Intracellular atp enhancer - Google Patents

Intracellular atp enhancer

Info

Publication number
CA3201273A1
CA3201273A1 CA3201273A CA3201273A CA3201273A1 CA 3201273 A1 CA3201273 A1 CA 3201273A1 CA 3201273 A CA3201273 A CA 3201273A CA 3201273 A CA3201273 A CA 3201273A CA 3201273 A1 CA3201273 A1 CA 3201273A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
composition according
atp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3201273A
Other languages
English (en)
French (fr)
Inventor
Miki Hiraoka
Ken Okamoto
Masuharu Hirano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN
Nippon Chemiphar Co Ltd
University of Tokyo NUC
Original Assignee
SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN
Nippon Chemiphar Co Ltd
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN, Nippon Chemiphar Co Ltd, University of Tokyo NUC filed Critical SCHOOL JURIDICAL PERSON HIGASHI-NIPPON-GAKUEN
Publication of CA3201273A1 publication Critical patent/CA3201273A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3201273A 2020-12-08 2021-12-08 Intracellular atp enhancer Pending CA3201273A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-203725 2020-12-08
JP2020203725 2020-12-08
PCT/JP2021/045045 WO2022124325A1 (ja) 2020-12-08 2021-12-08 細胞内atp増強剤

Publications (1)

Publication Number Publication Date
CA3201273A1 true CA3201273A1 (en) 2022-06-16

Family

ID=81973288

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3201273A Pending CA3201273A1 (en) 2020-12-08 2021-12-08 Intracellular atp enhancer

Country Status (8)

Country Link
US (1) US20240051971A1 (https=)
EP (1) EP4260860A4 (https=)
JP (1) JPWO2022124325A1 (https=)
KR (1) KR20230118083A (https=)
CN (2) CN121648131A (https=)
AU (1) AU2021398258A1 (https=)
CA (1) CA3201273A1 (https=)
WO (1) WO2022124325A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025258615A1 (ja) * 2024-06-12 2025-12-18 学校法人日本医科大学 運動機能向上剤、及びそれを含む医薬組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0219354Y2 (https=) 1984-09-13 1990-05-29
FR2608045B1 (fr) * 1986-12-12 1990-03-02 Chauvin Laboratoires Utilisation d'inhibiteurs de xanthine- oxydase, de piegeurs de radicaux libres oxygenes et de chelateurs du fer pour la fabrication d'une composition pharmaceutique destinee au traitement du glaucome et compositions pharmaceutiques destinees au traitement du glaucome
DK1757610T3 (da) 2004-06-14 2011-08-01 Nippon Chemiphar Co Kondenseret pyrimidinderivat og xanthinoxidaseinhibitor
CN101282934A (zh) * 2005-10-07 2008-10-08 安斯泰来制药株式会社 三芳基羧酸衍生物
ES2884123T3 (es) * 2013-03-15 2021-12-10 Xortx Therapeutics Inc Formulaciones de inhibidores de xantina oxidasa
US10413546B2 (en) * 2015-02-24 2019-09-17 National University Corporation Tottori University Drug for preventing and/or treating dementia
KR102600879B1 (ko) 2015-08-26 2023-11-09 가부시키가이샤 스타젠 세포 내 atp 증강제
JP6867142B2 (ja) 2016-11-17 2021-04-28 株式会社スタージェン パーキンソン症状改善用医薬
WO2018092911A1 (ja) 2016-11-21 2018-05-24 株式会社スタージェン 細胞内atp増強剤
JP6937134B2 (ja) * 2016-11-21 2021-09-22 株式会社スタージェン 細胞内atp増強剤
JP6966840B2 (ja) 2017-01-24 2021-11-17 株式会社スタージェン 神経変性疾患の改善用医薬
JP2018135278A (ja) 2017-02-20 2018-08-30 株式会社スタージェン 循環器疾患及び/又はミトコンドリア病の改善用医薬
TWI780270B (zh) * 2017-11-28 2022-10-11 靜岡縣公立大學法人 固體分散體
JP2021127289A (ja) 2018-04-27 2021-09-02 日本ケミファ株式会社 縮合ピリミジン誘導体
WO2020246528A1 (ja) * 2019-06-04 2020-12-10 日本ケミファ株式会社 痛風又は高尿酸血症の治療薬
CN110156131A (zh) 2019-06-17 2019-08-23 厦门翟苑日用品有限公司 一种幼儿园健康饮用水集中处理器

Also Published As

Publication number Publication date
CN116528840A (zh) 2023-08-01
AU2021398258A9 (en) 2024-02-08
US20240051971A1 (en) 2024-02-15
EP4260860A4 (en) 2024-11-06
KR20230118083A (ko) 2023-08-10
CN116528840B (zh) 2026-01-06
WO2022124325A1 (ja) 2022-06-16
EP4260860A1 (en) 2023-10-18
CN121648131A (zh) 2026-03-13
JPWO2022124325A1 (https=) 2022-06-16
WO2022124325A8 (ja) 2023-05-11
AU2021398258A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
US9447065B2 (en) Pharmaceutical composition
JP2021059551A (ja) フェニルアミノピリミジン誘導体を含む医薬組成物
EP3718548B1 (en) Solid dispersion
US20240051971A1 (en) Intracellular atp enhancer
JP2025061775A (ja) 痛風又は高尿酸血症の治療薬
HK40073463A (en) Therapeutic for gout or hyperuricemia
HK40073463B (en) Therapeutic for gout or hyperuricemia
EP3981470A1 (en) Enteric-coated preparation comprising xanthine oxidase inhibitor
CN116687961B (zh) 一种含有兰索拉唑及碳酸氢钠的干混悬剂及其制备方法
HK40027115B (zh) 固体分散体
AU2006207396A1 (en) Medicament that is intended for oral administration, comprising a cyclooxygenase-2 inhibitor, and preparation method thereof
HK1195743A (en) Medicinal composition

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241125

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241125

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241125

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251024

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251201

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251201

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260130

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260217

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260217

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260218